Immune checkpoint therapy is striking in cancer immunotherapy, and numerous effors have been taken in Immune checkpoint therapy. Many achievements have been gained in immune checkpoint therapy based on the research on various immune checkpoint targets, especially the most popular ones: PD-1, PD-L1 and CTLA-4. Achievements of immune checkpoint therapy in cancer is detailed below.
|Achievements of immune checkpoint therapy in cancer||Details|
|Nivolumab||A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against immune checkpoint PD1/PDCD1/CD279.|
|PembrolizumabIn||A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against immune checkpoint PD1/PDCD1/CD279.|
|Pidilizumab||A humanized, immunoglobulin (Ig) G1 monoclonal antibody directed against immune checkpoint PD1/PDCD1/CD279.|
|AMP-224||an anti-PD1/PDCD1/CD279 fusion protein, a recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD1/PDCD1/CD279 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1.|
|BMS-936559||a fully human, anti– PD-L1/B7-H1/CD274, IgG4 monoclonal antibody.|
|MEDI4736||A Fc optimized monoclonal antibody directed against PD-L1/B7-H1/CD27.|
|MPDL3280A||A human, Fc optimized, monoclonal antibody directed against the immune checkpoint PD-L1/B7-H1/CD274.|
|Avelumab||A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the immune checkpoint PD-L1/B7-H1/CD274.|
|Tremelimumab||A human immunoglobulin (Ig) G2 monoclonal antibody directed against the immune checkpoint CTLA-4/CD152.|
|MGA271||An engineered anti-B7-H3/CD276 mAb|
|Indoximod||A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO).|
|INCB024360||An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO)|
|Lirilumab||A fully humanized monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR)|
|BMS-986016||A monoclonal antibody directed against the immune checkpoint lymphocyte activation gene-3 (LAG-3).|
Howard (Jack) West, MD et al. Immune Checkpoint Inhibitors. JAMA Oncol. 2015;1(1):115.
Julie R. Brahmer et al. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunol Res August 2013 1; 85.
|Immune checkpoint therapy-combination||Immune checkpoint therapy-advantages|
|Immune checkpoint therapy-adverse effects|